Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study

Abstract

Lowering the commonly used dose of 0.625 mg CE + 2.5 mg MPA to 0.45 mg CE + 1.5 mg MPA does not significantly alter the inhibitory effect on bone and cartilage turnover in Asian women.

Ethnic differences in levels of bone and cartilage biomarkers and hormonal responsiveness in nine groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study

“…Interestingly, a significant correlation between baseline biomarkers and baseline estradiol levels, reported earlier 28 , was also apparent. The correlation was weak but statistically significant; it is noteworthy that it was negative and thus consistent with the biomarker-lowering effect of exogenous HT that we previously showed in this population 23 . Interestingly, in pre-and early perimenopausal women of the Study of Women's Health Across the Nation (SWAN), there was no significant association between the bone turnover markers osteocalcin and urinary N-telopeptide of type I collagen (NTx) compared to endogenous estradiol, a difference that may in part be due to the different menopausal status of women in the two studies 30 .…”

“…As part of the PAM study, we have recently reported responsiveness of bone and cartilage biomarkers to conjugated estrogens/ medroxyprogesteone acetate (CE/MPA) therapy in the overall study population 23 . The present Our study was conducted at large academic and clinical centers.…”

“…A recent publication from the Pan-Asia Menopause (PAM) study for the first time presented results of bone turnover and cartilage degradation biomarkers in a large group of Asian postmenopausal women 23 . The PAM study was a multinational clinical trial conducted in 11 Asian countries/regions.…”

Low-dose hormone therapy in postmenopausal women in China

“…A possible dose-response effect on bone mass was revealed in Chinese women. In a Pan-Asian study, markers of bone turnover were reduced by three doses of CEE/MPA 0.625/2.5, 0.45/1.5, 0.3/1.5 mg in postmenopausal Asian women after 6-month treatment, and the effects were strongest with the 0.625/2.5 mg dose and weakest with the 0.3/1.5 mg dose 48 . The BMD at the lumbar spine was increased by 4.16% vs. 1.51% in postmenopausal women after 12 months of treatment with transdermal estradiol 50 mg vs. 25 mg 33 .…”